Under construction – not a live service
Sign in
Taking people in TaiwanNo phase

Registry Collecting Data on a Rare Blood Cancer Called BPDCN

Collects information on patients with a rare blood cancer, BPDCN, and their treatments.

Plain-language title generated from the registry record
Registry title: Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Key facts

Where
Taichung, TaiwanSee the site

Where in Taiwan

  • China Medical University Children's HospitalTaichung, TaiwanTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Immune Oncology Research Institute
Trial code
NCT05430971
Record updated
5 June 2026
Original description
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.Read full original descriptionShow less

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare hematologic malignancy. Despite recent advances, at present there is no consensus on the optimal treatment of BPDCN. The optimal therapy of disease remains to be determined, and due to the rarity of cases, there is a need for international collaboration to collect data on BPDCN clinical presentations, diagnostics, treatment regimens and outcomes. Therefore, the objectives of this study are: (1) to build a large database of patients with BPDCN, (2) to investigate the characteristics and outcome of the disease with different treatment regimens, (3) to evaluate prognostic factors, and (4) to generate data-based prospective treatment recommendations.

Inclusion: Diagnosis of BPDCN; Signed informed consent form for prospective patients.

Exclusion: -.

ClinicalTrials.gov NCT05430971